A Random Assignment,Parallel Group, Open Label Comparison of Clinical Outcomes and Resource Utilization Among Bipolar Disorder Patients Receiving Either Long Acting Injectable Risperidone Microspheres (Risperdal Consta) or Other Second Generation Oral Antipsychotic Agents: A 15 Month Study.

Trial Profile

A Random Assignment,Parallel Group, Open Label Comparison of Clinical Outcomes and Resource Utilization Among Bipolar Disorder Patients Receiving Either Long Acting Injectable Risperidone Microspheres (Risperdal Consta) or Other Second Generation Oral Antipsychotic Agents: A 15 Month Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2016

At a glance

  • Drugs Aripiprazole; Olanzapine; Quetiapine; Risperidone; Ziprasidone
  • Indications Bipolar disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Feb 2009 Planned end date changed from 1 Jul 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 05 Jun 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top